Fig. 3

Robust increases of amyloid-β (Aβ) and paired helical filament (PHF)-tau levels in the Alzheimer’s disease (AD) cerebral organoid (CO) model. COs were subjected to analysis by ELISA, western blotting, Amylo-Glo staining, and immunostaining at day 70. (a) Aβ1–40 and Aβ1–42 levels in the lysates of CmC, CA, and CAP COs. The data represents the mean ± standard error of the mean (SEM); **P < 0.005 and ***P < 0.001 vs. CmC; ^###P < 0.001 vs. CA; n = 8 per sample. (b) Detection of amyloid plaques in the CA and CAP COs with Amylo-Glo staining. Scale bar = 100 μm. (c) Western blot analysis of the PHF-tau and total tau levels in the CmC, CA, and CAP COs in the lysates of each CO. The data represents the mean ± SEM; **P < 0.005 and ***P < 0.001 vs. CmC; ^##P < 0.005 vs. CA; n = 3 per sample. (E) Representative images of the immunohistochemistry showing the PHF-tau and TUJ1 in the CmC, CA and, CAP COs. Scale bar = 100 μm